| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H27ClO3 |
| Molecular Weight | 374.901 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@]1([H])[C@@]3(C)C(=CC2=O)C(Cl)=C[C@@]4([H])[C@]5([H])CC[C@](O)(C(C)=O)[C@@]5(C)CC[C@]34[H]
InChI
InChIKey=DUSHUSLJJMDGTE-ZJPMUUANSA-N
InChI=1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1
| Molecular Formula | C22H27ClO3 |
| Molecular Weight | 374.901 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cyproterone belongs to a group of medications known as steroidal antiandrogens. It suppresses testosterone and its metabolites. It has approximately three-fold lower potency as an antagonist of the androgen receptor relative to cyproterone acetate. Cyproterone acetate is used to treat advanced prostate cancer and acne.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
The 'uptake' of the anti-androgen cyproterone by human prostate slices was measured in two hyperplastic and two adenocarcinomatous glands. Samples of tissue slices of similar weight from the two hyperplastic glands were superfused with medium containing increasing amounts of cyproterone. There was no variation in the 'uptake' of cyproterone within the concentration range in the medium from 2.63 to 17.49 umol/litre.
